Descripción de la empresa
DarioHealth Corp. operates as a digital health entity that leverages data analytics and personalized coaching to deliver therapeutic interventions for conditions such as diabetes, hypertension, and weight management. This operational model places the firm within the Healthcare sector, specifically the Health Information Services industry, where it provides technology-driven solutions to support patient health outcomes across domestic and international markets. The company currently maintains a market capitalization of $46.50M, generates annual revenue of $22.36M, and employs a workforce of 160 individuals to execute its business strategy. These valuation and revenue figures indicate that DarioHealth Corp. occupies a niche position within the broader healthcare technology landscape, reflecting a relatively small market footprint compared to established pharmaceutical or large-cap digital health competitors.
Salud financiera
The financial performance of DarioHealth Corp. is characterized by a revenue of $22.36M, which stands in stark contrast to a net income of $-40,309,576, revealing a significant operational deficit where costs substantially exceed total earnings. The EBITDA stands at $-33,517,000, further highlighting the aggressive burn rate required to sustain its digital therapeutics platform and suite of solutions. Free cash flow is reported at $-11,204,875, indicating a consistent outflow of capital that limits the company's immediate financial flexibility and reliance on external funding sources to cover operational expenditures. The gross margin sits at 64.1%, suggesting that the cost of goods sold remains relatively low compared to sales, yet the operating margin is severely negative at -163.7%, implying that general and administrative expenses are consuming the entire gross profit and then some. Additionally, the profit margin is -186.6%, confirming that the company is incurring losses that exceed its total revenue generation. On the balance sheet, the company holds $26.02M in cash against $31.75M in debt, resulting in a debt-to-equity ratio of 46.74, which classifies the capital structure as highly leveraged and sensitive to interest rate fluctuations. Despite the high leverage, the current ratio of 3.76 suggests a robust short-term liquidity position capable of meeting immediate obligations without immediate distress. The return on equity is -59.6% and the return on assets is -20.0%, metrics that collectively reveal that management has not yet achieved profitability and is currently destroying shareholder value relative to the equity and assets deployed.
Evaluación de valoración
Valuation metrics for DarioHealth Corp. present a complex picture due to the absence of traditional profitability indicators, with a P/E Ratio (TTM) listed as N/A and a forward P/E of -14.64. The negative forward P/E implies that analysts or the market is pricing in future earnings growth necessary to overcome current losses, though the trajectory remains uncertain given the historical performance. The price-to-book ratio is 0.65, indicating that the market values the company at a discount to its net asset value, which often occurs in turnaround situations or for capital-intensive firms struggling to generate returns. An alternative perspective is provided by the price-to-sales ratio of 2.08 and an EV/EBITDA of -1.56, which suggest the market is valuing the firm primarily on its revenue generation and potential rather than current earnings power. The stock's 52-week trading range spans from a low of $5.93 to a high of $17.74, meaning the current market price sits below the 52-week high and reflects a period of significant price volatility. The beta of 1.28 indicates that the stock's price volatility is higher than the broader market, suggesting that DarioHealth Corp. experiences amplified swings in share price relative to general market movements.
Growth & Income
The growth profile of the company shows a revenue growth rate of -31.2% year-over-year, while earnings growth is N/A due to the reported net loss for the trailing twelve months. The contraction in revenue suggests a challenging operating environment or a reduction in market share, and the lack of earnings growth is directly correlated with the deep losses rather than a divergence in profitability metrics. Regarding income, the company does not distribute dividends to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of dividend payments implies that the company retains all available capital, theoretically directing funds toward operational restructuring or growth initiatives rather than providing passive income to investors. Consequently, the overall growth and income profile is defined by negative revenue momentum and a complete reliance on capital preservation rather than shareholder distribution or earnings expansion.